phase II clinical study
Lantern Pharma Gains FDA Clearance to Test LP-184 in Non-Small Cell Lung Cancer Subset
The firm will test the drug with immune checkpoint inhibitors in NSCLC patients with low PD-L1 expression and KEAP1 and/or STK11 mutations.
FDA Clears Ensoma's IND to Launch Immune Disorder Gene Therapy Trial
EN-374 is a gene therapy designed to treat X-linked chronic granulomatous disease by modifying hematopoietic stem cells in vivo.
Lantern to Test AI-Developed Drug in Triple-Negative Breast Cancer Trial
The firm will test LP-184 as a monotherapy and in combination with a PARP inhibitor in patients who have DNA damage repair gene mutations.
Marengo Begins Phase Ib/II Trial of Invikafusp Alfa, Trodelvy in Certain Breast Cancers
The study will include two cohorts of breast cancer patients: triple-negative breast cancer and HR-positive, HER2-negative breast cancer.
Isarna to Discuss ASO for Wet AMD, Diabetic Macular Edema With Regulators
Phase II trial results indicated that treatment with the firm's antisense oligonucleotide led to stable or improved best-corrected visual acuity.
Apr 30, 2025
Mar 28, 2025